Cibus, Inc.
CBUSHealthcare|Biotechnology|US
$1.18
+0.04 (+3.51%)
Cash / Share
$0.27
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07905053 A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of CBT-248 in Healthy Adult Participants | Chronic Pancreatitis | P1 | Recruiting | 32 | RCT, Double-blind | CBT-248, CBT-248 Placebo |